NMOtion™ Blog

Discussing NMO Research and Advocacy

Press Release: FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder

Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS)…

Click here to read the full release.

Launch Dashboard


Fast Facts about NMOSD